Synthesis and biological assessment of ciprofloxacin-derived 1,3,4-thiadiazoles as anticancer agents. 2020

Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
Department of Medicinal Chemistry, Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

The quinolone-3-carboxylic acid scaffold is essential structure for antibacterial activity of fluoroquinolones such as ciprofloxacin. Modification of 3-carboxylic functionality in this structure can be used for switching its activity from antibacterial to anticancer. Accordingly, a series of C-3 modified ciprofloxacin derivatives containing N-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-carboxamide moiety was synthesized as novel anticancer agents. Most of compounds showed significant activity against MCF-7, A549 and SKOV-3 cancer cells in the MTT assay. In particular, compounds 13a-e and 13g were found to be as potent as standard drug doxorubicin against MCF-7 cell line (IC50s = 3.26-3.90 µM). Furthermore, the 4-fluorobenzyl derivatives 13h and 14b with IC50 values of 3.58 and 2.79 µM exhibited the highest activity against SKOV-3 and A549 cells, being as potent as doxorubicin. Two promising compounds 13e and 13g were further tested for their apoptosis inducing activity and cell cycle arrest. Both compounds could significantly induce apoptosis in MCF-7 cells, while compound 13e was more potent apoptosis inducer resulting in an 18-fold increase in the proportion of apoptotic cells at the IC50 concentration in MCF-7 cells. The cell cycle analysis revealed that compounds 13e and 13g could increase cell portions in the sub-G1 phase, inducing oligonucleosomal DNA fragmentation and apoptosis confirmed by comet assay.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013830 Thiadiazoles Heterocyclic compounds composed of a five-membered heterocyclic ring which contains one sulfur and two nitrogen atoms. Thiadiazole
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
January 2013, European journal of medicinal chemistry,
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
December 1990, Farmaco (Societa chimica italiana : 1989),
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
December 2023, Molecular diversity,
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
November 2021, Molecules (Basel, Switzerland),
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
October 2010, European journal of medicinal chemistry,
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
January 2019, Iranian journal of pharmaceutical research : IJPR,
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
December 2020, Acta pharmaceutica (Zagreb, Croatia),
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
January 2015, Chemical & pharmaceutical bulletin,
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
October 2022, Molecules (Basel, Switzerland),
Hamideh Ahadi, and Mohammad Shokrzadeh, and Zahra Hosseini-Khah, and Nasrin Ghassemi Barghi, and Majid Ghasemian, and Elnaz Emadi, and Mehryar Zargari, and Nima Razzaghi-Asl, and Saeed Emami
October 2012, European journal of medicinal chemistry,
Copied contents to your clipboard!